International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia (A randomized Phase III study conducted by the AIEOP-BFM study group)
Application of innovative molecular profiling techniques to improve diagnosis of paediatric central nervous system tumours and develop an accredited Australasian molecular profiling service.
A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma
≥ 1 year
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital
A pilot study to test the feasibility and safety and efficacy of the addition of the BiTE antibody Blinatumomab to the Interfant-06 backbone in infants with MLL-rearranged acute lymphoblastic leukemia (A collaborative study of the Interfant network)
Cancer Information Registry for Children and Adolescents in Australia
No limit
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent paediatric Adamantinomatous Craniopharyngioma
1 year
|
39 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Royal Children’s Hospital, Perth Children’s Hospital
Phase I/II Trial of Deflexifol for Refractory or Recurrent Paediatric CNS Tumours
12 months
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Westmead Adult Hospital
FaR-RMS (RG_17-247)
An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
No limit
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Westmead Adult Hospital
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Royal Adelaide Hospital
INTER-EWING-1 (RG_21-151)
International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma – Trial 1 (INTER-EWING-1)
> 2 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital
International collaborative treatment protocol for infants under one year with KMT2Arearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia
1 day
|
1 year
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma
Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain tumour.
7 years
|
21 years
John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Sir Charles Gardiner Hospital
International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting with Spinal Canal Involvement (SCI)
< 18 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
A Phase II Study of Panobinostat in Paediatric& Adolescent and Young Adult Patients with Solid Tumours Including Osteosarcoma& Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours and Neuroblastoma
< 40 years
N/A
CNS tumours, Peripheral neuroblastic tumours, Soft tissue and bone tumours
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer: A Phase I/II precision oncology basket trial of precision guided molecularly-targeted agents in children and adolescents with advanced brain and solid tumours
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
Multicentre, investigator-initiated phase I/II clinical trial to assess safety and efficacy of personalised mRNA vaccine targeting tumour-associated neoantigens in children and young adults with high-risk brain tumours: the PaedNeoVax study
6 months
|
25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Single Arm, Pilot of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
6 months
|
25 years
Queensland Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGS) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
2 years
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Tovorafenib for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
1 year
|
39 years
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
- Chris O'Brien Lifehouse - Peter MacCallum Cancer Centre - Princess Alexandra Hospital - Royal Adelaide Hospital - Sir Charles Gardiner Hospital
rEECur (RG_13-277)
International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma
≥ 2 years (no upper limit)
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital, Chris O’Brien Lifehouse, Peter MacCallum Cancer Centre, Princess Alexandra Hospital, Royal Adelaide Hospital, Sir Charles Gardiner Hospital
Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing Sarcoma
A Phase II Canadian paediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma
Phase 1 Evaluation Of Ly2606368& A Molecularly Targeted Chk1/2 Inhibitor Therapy& In Combination With Cyclophosphamide Or Gemcitabine For Children And Adolescents With Refractory Or Recurrent Group 3/Group 4 Or Shh Medulloblastoma Brain Tumors
Phase II Study of Ribociclib and Everolimus Following Radiotherapy in paediatric and Young Adult Patients Newly Diagnosed with HighGrade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways: A treatment arm within TarGeT
12 months
|
39 years
John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Phase 2 Study of Olutasidenib with Temozolomide as Maintenance Therapy in paediatric and Young Adult Patients Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG), which Harbor IDH1 Mutations
12 years
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
A Pilot Study of Lorlatinib for Treatment of Children with Newly Diagnosed High-Grade Glioma with ROS-1 and ALK Fusion
1 year
|
21 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead
Molecularly-Guided Phase II Umbrella Trial for Children, Adolescents, and Young Adults Newly Diagnosed with High-Grade Glioma (HGG), including Diffuse Intrinsic Pontine Glioma (DIPG) – SCREENING PROTOCOL
12 months
|
39 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
A phase II study of trametinib in paediatric, adolescent and young adult patients with neurofibromatosis type 1 associated plexiform neurofibromas or progressive optic pathway gliomas
A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients with Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG)
12 months
|
25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Children’s Hospital at Westmead
A Pilot Study to Investigate Safety and Efficacy of Weekly Combination of Intravenous Vinblastine with Oral Type II RAF Inhibitor Tovorafenib in paediatric Patient with Recurrent/ Progressive RAF Altered (non-NF1) Low Grade Gliomas
≤ 25 years
Queensland Children’s Hospital, John Hunter Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital
Queensland Children’s Hospital, John Hunter Children’s Hospital, Sydney Children’s Hospital, Monash Health Clayton, Royal Children’s Hospital, Women’s and Children’s Hospital, Perth Children’s Hospital, Royal Hobart Hospital, Children’s Hospital at Westmead, Starship Children’s Hospital, Christchurch Hospital
Breast tumours, CNS tumours, Digestive system tumours, Endocrine tumours, Eye tumours, Female genital tumours, Genetic tumour syndromes, Germ cell tumours, Haematolymphoid disorders, Head and neck tumours, Peripheral neuroblastic tumours, Renal and male genital tumours, Skin tumours, Soft tissue and bone tumours, Thoracic tumours
